IL1F10 and myocardial infarction: Wei et al. followed up their 2015 investigation of IL-38′s contribution to MI pathology with subsequent in vivo mouse studies, which showed that treatment with recombinant IL-38 resulted in a disruption of cardiac fibrosis and improved ventricular function [89].